de Barclays Neurocrine Biosciences NBIX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 54.7 M | Comprar |
324,807
+80,823
| +33% | +USD 12 M | 0.01% | 701 |
|
|
2026
Q1 | USD 32.1 M | Vender |
243,984
-8,257
| -3% | -USD 1.1 M | 0.01% | 896 |
|
|
2025
Q4 | USD 35.8 M | Vender |
252,241
-51,737
| -17% | -USD 7.5 M | 0.01% | 930 |
|
|
2025
Q3 | USD 42.7 M | Comprar |
303,978
+32,588
| +12% | +USD 4.42 M | 0.01% | 851 |
|
|
2025
Q2 | USD 34.1 M | Comprar |
271,390
+71,172
| +36% | +USD 8.16 M | 0.01% | 869 |
|
|
2025
Q1 | USD 22.1 M | Comprar |
200,218
+21,850
| +12% | +USD 2.77 M | 0.01% | 983 |
|
|
2024
Q4 | USD 24.3 M | Vender |
178,368
-3,223
| -2% | -USD 399 k | 0.01% | 1018 |
|
|
2024
Q3 | USD 20.9 M | Comprar |
181,591
+19,202
| +12% | +USD 2.63 M | 0.01% | 1047 |
|
|
2024
Q2 | USD 22.4 M | Vender |
162,389
-94,850
| -37% | -USD 13 M | 0.01% | 897 |
|
|
2024
Q1 | USD 35.5 M | Comprar |
257,239
+25,071
| +11% | +USD 3.42 M | 0.01% | 747 |
|
|
2023
Q4 | USD 30.6 M | Comprar |
232,168
+53,905
| +30% | +USD 6.2 M | 0.01% | 884 |
|
|
2023
Q3 | USD 20.1 M | Vender |
178,263
-16,259
| -8% | -USD 1.71 M | 0.01% | 757 |
|
|
2023
Q2 | USD 18.3 M | Vender |
194,522
-53,472
| -22% | -USD 5.22 M | 0.01% | 755 |
|
|
2023
Q1 | USD 25.1 M | Comprar |
247,994
+92,208
| +59% | +USD 9.6 M | 0.01% | 763 |
|
|
2022
Q4 | USD 18.6 M | Comprar |
155,786
+9,183
| +6% | +USD 1.08 M | 0.01% | 929 |
|
|
2022
Q3 | USD 15.6 M | Comprar |
146,603
+27,837
| +23% | +USD 2.82 M | 0.02% | 698 |
|
|
2022
Q2 | USD 11.6 M | Comprar |
118,766
+4,055
| +4% | +USD 374 k | 0.01% | 951 |
|
|
2022
Q1 | USD 10.8 M | Vender |
114,711
-17,676
| -13% | -USD 1.5 M | 0.01% | 878 |
|
|
2021
Q4 | USD 11.3 M | Vender |
132,387
-23,000
| -15% | -USD 2.12 M | ﹤0.01% | 1206 |
|
|
2021
Q3 | USD 14.9 M | Vender |
155,387
-47,617
| -23% | -USD 4.5 M | 0.01% | 1013 |
|
|
2021
Q2 | USD 19.8 M | Comprar |
203,004
+127,576
| +169% | +USD 12.2 M | 0.01% | 904 |
|
|
2021
Q1 | USD 7.34 M | Comprar |
75,428
+36,573
| +94% | +USD 3.84 M | ﹤0.01% | 1232 |
|
|
2020
Q4 | USD 3.72 M | Vender |
38,855
-33,124
| -46% | -USD 3.2 M | ﹤0.01% | 1732 |
|
|
2020
Q3 | USD 6.92 M | Comprar |
71,979
+28,431
| +65% | +USD 3.29 M | ﹤0.01% | 1212 |
|
|
2020
Q2 | USD 5.31 M | Comprar |
43,548
+12,558
| +41% | +USD 1.39 M | ﹤0.01% | 1332 |
|
|
2020
Q1 | USD 2.68 M | Vender |
30,990
-40,014
| -56% | -USD 3.92 M | ﹤0.01% | 2013 |
|
|
2019
Q4 | USD 7.63 M | Comprar |
71,004
+18,501
| +35% | +USD 1.94 M | ﹤0.01% | 1601 |
|
|
2019
Q3 | USD 4.73 M | Vender |
52,503
-32,557
| -38% | -USD 3.04 M | ﹤0.01% | 1898 |
|
|
2019
Q2 | USD 7.18 M | Comprar |
85,060
+1,818
| +2% | +USD 149 k | ﹤0.01% | 1559 |
|
|
2019
Q1 | USD 7.33 M | Comprar |
83,242
+6,091
| +8% | +USD 509 k | 0.01% | 1419 |
|
|
2018
Q4 | USD 5.51 M | Comprar |
77,151
+52,969
| +219% | +USD 5.07 M | ﹤0.01% | 1529 |
|
|
2018
Q3 | USD 2.97 M | Comprar |
24,182
+1,758
| +8% | +USD 199 k | ﹤0.01% | 2420 |
|
|
2018
Q2 | USD 2.2 M | Vender |
22,424
-15,989
| -42% | -USD 1.43 M | ﹤0.01% | 2500 |
|
|
2018
Q1 | USD 3.19 M | Comprar |
38,413
+5,274
| +16% | +USD 445 k | ﹤0.01% | 2003 |
|
|
2017
Q4 | USD 2.57 M | Vender |
33,139
-337
| -1% | -USD 23 k | ﹤0.01% | 2212 |
|
|
2017
Q3 | USD 2.05 M | Comprar |
33,476
+13,285
| +66% | +USD 701 k | ﹤0.01% | 2338 |
|
|
2017
Q2 | USD 928 k | Comprar |
20,191
+9,618
| +91% | +USD 467 k | ﹤0.01% | 2951 |
|
|
2017
Q1 | USD 458 k | Vender |
10,573
-90,042
| -89% | -USD 3.86 M | ﹤0.01% | 3485 |
|
|
2016
Q4 | USD 3.9 M | Comprar |
100,615
+93,196
| +1,256% | +USD 4.22 M | ﹤0.01% | 1565 |
|
|
2016
Q3 | USD 375 k | Vender |
7,419
-29,147
| -80% | -USD 1.45 M | ﹤0.01% | 3466 |
|
|
2016
Q2 | USD 1.66 M | Comprar |
36,566
+13,129
| +56% | +USD 604 k | ﹤0.01% | 2167 |
|
|
2016
Q1 | USD 914 k | Vender |
23,437
-27,030
| -54% | -USD 1.07 M | ﹤0.01% | 2599 |
|
|
2015
Q4 | USD 2.83 M | Vender |
50,467
-34,791
| -41% | -USD 1.77 M | ﹤0.01% | 1740 |
|
|
2015
Q3 | USD 3.32 M | Comprar |
85,258
+65,748
| +337% | +USD 3.18 M | ﹤0.01% | 1661 |
|
|
2015
Q2 | USD 915 k | Vender |
19,510
-6,208
| -24% | -USD 263 k | ﹤0.01% | 2953 |
|
|
2015
Q1 | USD 1 M | Vender |
25,718
-139,358
| -84% | -USD 4.98 M | ﹤0.01% | 2983 |
|
|
2014
Q4 | USD 3.63 M | Comprar |
165,076
+12,717
| +8% | +USD 241 k | ﹤0.01% | 1977 |
|
|
2014
Q3 | USD 2.28 M | Comprar |
152,359
+106,580
| +233% | +USD 1.59 M | ﹤0.01% | 2542 |
|
|
2014
Q2 | USD 641 k | Comprar |
45,779
+14,918
| +48% | +USD 211 k | ﹤0.01% | 3745 |
|
|
2014
Q1 | USD 494 k | Comprar |
30,861
+547
| +2% | +USD 9.36 k | ﹤0.01% | 3971 |
|
|
2013
Q4 | USD 273 k | Vender |
30,314
-80,912
| -73% | -USD 790 k | ﹤0.01% | 4691 |
|
|
2013
Q3 | USD 1.22 M | Comprar |
111,226
+37,893
| +52% | +USD 521 k | ﹤0.01% | 3126 |
|
|
2013
Q2 | USD 981 k | Comprar |
+73,333
| Nuevas | +USD 901 k | ﹤0.01% | 3386 |
|
Otros fondos que tienen NBIX en su cartera
Posición de Barclays en NBIX: resumen de T2 2026
Barclays aumentó su participación en Neurocrine Biosciences (NBIX) en 33% durante T2 2026, al comprar aproximadamente USD 12 M y elevar la posición a 324,807 acciones con un valor de USD 54.7 M. La posición representa 0.01% de la cartera y ocupa el puesto #701.
Barclays reportó por primera vez una posición en NBIX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 784 fondos que sigue Wall St. Rank mantienen una posición en NBIX.
- Al cierre de T2 2026, Barclays tenía 324,807 acciones de Neurocrine Biosciences con un valor de USD 54.7 M.
- Barclays compró 80,823 acciones de Neurocrine Biosciences en T2 2026, por un monto estimado de USD 12 M.
- Neurocrine Biosciences representó 0.01% de la cartera de Barclays en T2 2026 y fue su posición número 701.
- Barclays reportó por primera vez una posición en Neurocrine Biosciences en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 784 fondos que sigue Wall St. Rank tenían Neurocrine Biosciences en cartera.
Según el Informe 13F de Barclays correspondiente a T2 2026, presentado el 14 ago 2026.